Obesity
Posthoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.
While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism.
Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.
Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments.
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.
Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.
A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.
Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.
PRESS RELEASES